Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?

Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

Volumn 2012, Issue , 2012, Pages 354-361

  Rajkumar, S Vincent ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; BORTEZOMIB; CARFILZOMIB; DRUG DERIVATIVE; LENALIDOMIDE; MELPHALAN; OLIGOPEPTIDE; PREDNISONE; PYRAZINE DERIVATIVE; THALIDOMIDE;

BIOLOGICAL MODEL; CLINICAL TRIAL (TOPIC); DRUG THERAPY; HUMAN; METHODOLOGY; MULTIPLE MYELOMA; ONCOLOGY; REVIEW; RISK; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY; HUMANS; MEDICAL ONCOLOGY; MELPHALAN; MODELS, BIOLOGICAL; MULTIPLE MYELOMA; OLIGOPEPTIDES; PREDNISONE; PYRAZINES; RISK; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84873037719     PISSN: None     EISSN: 15204383     Source Type: Journal    
DOI: 10.1182/asheducation.v2012.1.354.3798330     Document Type: Review

References (0)